Metformin Accord

Metformin, the active ingredient in Metformin Accord, is a Biguanide presented as a tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus, often as part of a comprehensive lifestyle and pharmacologic regimen.

GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution with robust regulatory support.

Metformin Accord belongs to the biguanide class and is used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial blood glucose levels. - Prediabetes: helps delay progression to overt diabetes when combined with diet and exercise. - Polycystic ovary syndrome (PCOS): may improve insulin resistance and restore ovulatory function.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term use. - Hepatic dysfunction: elevated liver enzymes. - Skin rash or hypersensitivity reactions. - Pancreatitis: inflammation of the pancreas.

Metformin should be used with careful clinical assessment and monitoring.

- Renal function assessment: avoid in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic disease: use cautiously in patients with liver dysfunction. - Cardiovascular status: monitor in patients with heart failure. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Blood glucose monitoring: adjust therapy based on glycaemic response. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metformin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast media: can precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Trimethoprim: can reduce renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Warfarin: may enhance anticoagulant effect, requiring INR checks. - Digoxin: increased risk of gastrointestinal upset.